Evidence map›Paper›PMID 27792461›Full record

ArticleVirulence2017

Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.

Firas Elmastour, Hela Jaïdane, Mehdi Benkahla, Leila Aguech-Oueslati, Famara Sane, Aymen Halouani, Ilka Engelmann, Antoine Bertin, Moncef Mokni, Jawhar Gharbi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Firas Elmastoura Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Hela Jaïdaneb Université de Monastir , Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Mehdi Benkahlaa Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Leila Aguech-Oueslatia Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Famara Sanea Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Aymen Halouanib Université de Monastir , Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Ilka Engelmanna Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Antoine Bertina Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Moncef Moknid Université de Sousse , CHU Farhat Hached, Service d'Anatomopathologie , Sousse , Tunisia.
Jawhar Gharbib Université de Monastir , Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Mahjoub Aounib Université de Monastir , Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Enagnon K Alidjinoua Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Didier Hobera Université de Lille , Faculté de Médecine, CHU Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Centre Hospitalier Universitaire de Lille · FRUniversity of Monastir · TNUniversité de Lille · FRTunis El Manar University · TNUniversity of Sousse · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In previous studies it was shown that inoculation of Swiss albino mice with CV-B4 E2 resulted in the production of serum IgG capable of enhancing the CV-B4 E2 infection of murine spleen cells cultures. To investigate whether such an enhancing activity of serum can play a role in vivo, we decided to study the CV-B4 E2 infection in mice exposed to successive inoculations of virus. In Swiss albino mice infected with CV-B4 E2 at the age of 21 days, anti-CV-B4 E2 neutralizing and enhancing activities of their serum peaked after 55 d. In contrast, mice inoculated at the age of 55 d expressed much lower activities. Despite the neutralizing activity of serum, CV-B4 E2 inoculated a second time to 55 day-old animals spread into the host. At the age of 72 and 89 d the levels of viral RNA and infectious particles were higher in organs of animals exposed to 2 successive infections compared with animals infected once at the age of 21 d or 55 d. In animals with 2 successive inoculations of CV-B4 E2 there was a relationship between the anti-CV-B4 E2 enhancing activity of serum and the level of viral RNA in organs and an enhancement of pathology was observed as displayed by histological analysis of pancreas and hyperglycaemia. Altogether our data strongly suggest that an anti-CV-B4 E2 enhancing activity in the host can play a role in the outcome of a secondary infection with this virus.

Indexed as

AnimalsAntibodies, BlockingAntibodies, NeutralizingAntibodies, ViralCell LineCoxsackievirus InfectionsEnterovirus B, HumanHost-Pathogen InteractionsHumansHyperglycemiaMiceNeutralization TestsPancreasRNA, ViralSpleenViral LoadAntibodies, BlockingAntibodies, NeutralizingAntibodies, ViralRNA, Viralenterovirushyperglycaemiain vivopancreasreinfection

Identifiers

PMID27792461
PMCPMC5626334
OpenAlexW2545094650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.